Episode

From MIT Chemistry to VC: Navigating the Biotech Startup Landscape with Neena Kadaba

Podcast
The NextGen VC Podcast
Published
Nov 9, 2023
Duration seconds
1639
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/nextgenvcpodcast/episodes/From-MIT-Chemistry-to-VC-Navigating-the-Biotech-Startup-Landscape-with-Neena-Kadaba-e2bm2qv
Audio
https://anchor.fm/s/e77f3ea0/podcast/play/78367007/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2023-10-8%2Faab38043-11b0-30ea-e2bd-02adc8c2616c.mp3
JSON
/v1/public/podcasts/the-nextgen-vc-podcast-6617779/episodes/from-mit-chemistry-to-vc-navigating-the-biotech-startup-landscape-with-neena-kadaba
Markdown
/podcast/the-nextgen-vc-podcast-6617779/from-mit-chemistry-to-vc-navigating-the-biotech-startup-landscape-with-neena-kadaba.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-nextgen-vc-podcast-6617779/episodes/from-mit-chemistry-to-vc-navigating-the-biotech-startup-landscape-with-neena-kadaba/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-nextgen-vc-podcast-6617779/from-mit-chemistry-to-vc-navigating-the-biotech-startup-landscape-with-neena-kadaba.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Neena Kadaba, an entrepreneur in residence at Apple Tree Partners, shares her journey from studying chemistry at MIT to becoming a venture capitalist in the biotech industry. She discusses her initial attraction to science, her experience as a Kauffman Fellow, and her role at Apple Tree Partners, a life science venture fund that creates biotech companies to translate emerging science into new therapies. Neena emphasizes the importance of curiosity, communication, and building a network in the world of venture capital. She also shares insights into dealing with challenges and struggles in startups, from financing to team management. This episode offers valuable advice and a glimpse into the evolving landscape of biotech investing.